
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is a commercial-stage biotechnology company with a strong portfolio of drug candidates targeting multiple therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Its flagship product, KIMMTRAK, has shown significant survival benefits in clinical trials and has high market penetration. With multiple upcoming catalysts, including late-stage readouts and potential label expansions, Immunocore has a strong outlook for growth in the coming years. Risks include clinical development, competition, and commercialization uncertainties, but a risk-adjusted DCF and SOTP-based analysis yields a firm value of approximately $5 billion or a possible $100 price target.
Bears say
Immunocore Holdings is facing potential market competition, as IDEAYA's program for HLA-A*02:01-negative patients may be able to treat the entire population of mUM and offers more flexibility in the longer term. Additionally, the company's financials show a need for additional funds, and there is no guarantee of obtaining favorable financing. Although KIMMTRAK has shown promising results, the company faces uncertainties in maintaining its market position and financial stability.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares